OPN-2853
- Generic Name
- OPN-2853
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
- Conditions
- Gynecologic NeoplasmsEpithelial Ovarian Cancer
- Interventions
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Opna Bio LLC
- Target Recruit Count
- 37
- Registration Number
- NCT04493619
- Locations
- 🇺🇸
University of Virginia Health Systems, Charlottesville, Virginia, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of Oklahoma - Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- Conditions
- Refractory Acute Myeloid Leukemia (AML)Relapsed Acute Myeloid Leukemia (AML)High-risk Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Opna Bio LLC
- Target Recruit Count
- 22
- Registration Number
- NCT03787498
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore, Maryland, United States
🇺🇸NewYork-Presbyterian / Weill Cornell Medical Center, New York, New York, United States
A Study of PLX2853 in Advanced Malignancies.
- Conditions
- Small Cell Lung CancerUveal MelanomaOvarian Clear Cell CarcinomaNon-Hodgkin LymphomaAdvanced MalignanciesSolid TumorDiffuse Large B Cell LymphomaFollicular Lymphoma
- Interventions
- First Posted Date
- 2017-09-29
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Opna Bio LLC
- Target Recruit Count
- 49
- Registration Number
- NCT03297424
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center / University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.